ADGRG6 and neoplasm: The detection rates of the studied mutations in urine were close to the expected rates based on the reported frequencies of these genetic alterations in tumor tissue (35.7% vs. 31.4–53.0% for the GPR126 sixth intron and 57.1% vs. 59.0–77.0% for the TERT promoter, respectively) [13,14,15,20,21,22].